3
Announcements
Trials
Browse
Landscape
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Observational
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Colorectal Neoplasms
187
Carcinoma, Non-Small-Cell Lung
85
Breast Neoplasms
66
Neoplasms
62
Ovarian Neoplasms
59
Glioblastoma
40
Carcinoma, Hepatocellular
36
Neoplasm Metastasis
32
Colonic Neoplasms
27
Carcinoma, Renal Cell
24
Fallopian Tube Neoplasms
23
Uterine Cervical Neoplasms
21
Rectal Neoplasms
17
Pancreatic Neoplasms
17
Lung Neoplasms
17
Stomach Neoplasms
15
Liver Neoplasms
15
Brain Neoplasms
14
Non-Squamous Non-Small Cell Lung Cancer
13
Endometrial Neoplasms
11
Recurrence
10
Glioma
10
Carcinoma, Ovarian Epithelial
10
Triple Negative Breast Neoplasms
9
Melanoma
9
Gastrointestinal Neoplasms
9
Advanced Solid Tumors
9
Solid Cancers
7
Peritoneal Neoplasms
7
Parkinson Disease 4, Autosomal Dominant Lewy Body
7
Interventions
tremelimumab
1
durvalumab
1
atezolizumab
1
Bevacizumab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
INDUSTRY
×
Unresectable Hepatocellular Carcinoma
×
Bevacizumab
×
Clear all
NCT06117891
2026-05-12
REFINE-IO
Bayer
Active not recruiting
300 enrolled